These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 17868339)

  • 1. Preoperative serum CA125 levels do not predict suboptimal cytoreductive surgery in epithelial ovarian cancer.
    Arits AH; Stoot JE; Botterweck AA; Roumen FJ; Voogd AC
    Int J Gynecol Cancer; 2008; 18(4):621-8. PubMed ID: 17868339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Barlow TS; Przybylski M; Schilder JM; Moore DH; Look KY
    Int J Gynecol Cancer; 2006; 16(2):496-500. PubMed ID: 16681717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer.
    Memarzadeh S; Lee SB; Berek JS; Farias-Eisner R
    Int J Gynecol Cancer; 2003; 13(2):120-4. PubMed ID: 12657110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study to evaluate the utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer.
    Gilani MM; Karimi Zarchi M; Ghaemmaghami F; Behtash N; Mousavi AS; Ansaripoor S
    Gynecol Oncol; 2007 Jun; 105(3):780-3. PubMed ID: 17433423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel index for preoperative, non-invasive prediction of macro-radical primary surgery in patients with stage IIIC-IV ovarian cancer-a part of the Danish prospective pelvic mass study.
    Karlsen MA; Fagö-Olsen C; Høgdall E; Schnack TH; Christensen IJ; Nedergaard L; Lundvall L; Lydolph MC; Engelholm SA; Høgdall C
    Tumour Biol; 2016 Sep; 37(9):12619-12626. PubMed ID: 27440204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.
    Braicu EI; Fotopoulou C; Van Gorp T; Richter R; Chekerov R; Hall C; Butz H; Castillo-Tong DC; Mahner S; Zeillinger R; Concin N; Vergote I; Sehouli J
    Gynecol Oncol; 2013 Feb; 128(2):245-51. PubMed ID: 23178313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
    Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
    J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model for Prediction of Optimal Debulking of Epithelial Ovarian Cancer.
    Arab M; Jamdar F; Sadat Hosseini M; Ghodssi- Ghasemabadi R; Farzaneh F; Ashrafganjoei T
    Asian Pac J Cancer Prev; 2018 May; 19(5):1319-1324. PubMed ID: 29802693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level.
    Obeidat B; Latimer J; Crawford R
    Gynecol Obstet Invest; 2004; 57(3):153-6. PubMed ID: 14726621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
    Feng LY; Liao SB; Li L
    J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Zhang D; Jiang YX; Luo SJ; Zhou R; Jiang QX; Linghu H
    Clin Chim Acta; 2018 Sep; 484():32-35. PubMed ID: 29702068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy.
    Pelissier A; Bonneau C; Chéreau E; de La Motte Rouge T; Fourchotte V; Daraï E; Rouzier R
    Gynecol Oncol; 2014 Dec; 135(3):542-6. PubMed ID: 25223808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma.
    Chi DS; Venkatraman ES; Masson V; Hoskins WJ
    Gynecol Oncol; 2000 May; 77(2):227-31. PubMed ID: 10785469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative CA-125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer.
    Gemer O; Segal S; Kopmar A
    Acta Obstet Gynecol Scand; 2001 Jun; 80(6):583-5. PubMed ID: 11380298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer.
    Frederick PJ; Ramirez PT; McQuinn L; Milam MR; Weber DM; Coleman RL; Gershenson DM; Landen CN
    Int J Gynecol Cancer; 2011 Jul; 21(5):831-6. PubMed ID: 21613957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is postoperative CA125 level in patients with epithelial ovarian cancer reliable to guess the optimality of surgery?
    Ghaemmaghami F; Akhavan S
    Eur J Gynaecol Oncol; 2011; 32(2):192-5. PubMed ID: 21614912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer.
    Brockbank EC; Ind TE; Barton DP; Shepherd JH; Gore ME; A'Hern R; Bridges JE
    Int J Gynecol Cancer; 2004; 14(1):42-50. PubMed ID: 14764028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
    Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
    Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.